Factors influencing reticulophagocytic function in insulin-treated diabetes.
The splenic component of reticulophagocytic function (RPF) was examined in 29 insulin-treated diabetic subjects (13 type I and 16 type II) by measurement of clearance of altered, radiolabeled, autologous erythrocytes. Double-isotope studies were performed with cells altered by: (1) preincubation with N-ethylmaleimide (NEM) and (2) coating with IgG antibody to the Rhesus (Rh) D antigen, labeled with 99mTc and 51Cr, respectively. HLA typing for the A, B, and DR loci was performed in those patients showing a defect in the clearance of IgG-coated cells. Values for half-life (t1/2) were correlated with the incidence of diabetic complications, levels of HbA1, and circulating immune complexes (CIC). Two patterns of abnormal clearance were observed: first, an isolated defect of IgG-coated cell clearance in 7 patients (3 had the HLA B8/DR3 haplotype) and second, abnormal removal of both types of cell in a further 7 patients (3 had B8/DR3). There was no correlation between half-lives as measured by the two methods, although exclusion of the patients with a defect of IgG-coated cell clearance alone yielded a highly significant correlation for the remaining 15 Rh-positive patients (P less than 0.01). Abnormalities of IgG-coated cell clearance were more frequent in patients with HbA1 greater than 9% (P less than 0.02), while t1/2 of NEM-altered cells was significantly greater in patients with CIC (P less than 0.05). There was no correlation between t1/2 and the incidence of peripheral complications.(ABSTRACT TRUNCATED AT 250 WORDS)
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000936:Antigen-Antibody Complex / Q000032:analysis*; D002860:Chromium Radioisotopes; D003165:Complement System Proteins / Q000032:analysis*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000276:immunology; D003928:Diabetic Nephropathies / Q000276:immunology; D003930:Diabetic Retinopathy / Q000276:immunology; D004912:Erythrocytes; D005260:Female; D006680:HLA Antigens / Q000032:analysis; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007328:Insulin / Q000627:therapeutic use*; D008264:Macrophages / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011817:Rabbits; D012156:Reticulocytes / Q000276:immunology*; D013154:Spleen / Q000098:blood supply; D013667:Technetium
D000936:Antigen-Antibody Complex; D002860:Chromium Radioisotopes; D006680:HLA Antigens; D007074:Immunoglobulin G; D007328:Insulin; D013667:Technetium; D003165:Complement System Proteins